Saira Ahmed
Abstract
Visual loss remains the most feared complication of giant cell arteritis (GCA), often resulting in permanent disability despite prompt treatment. Although the classical features of GCA are well described, real-world presentations of GCA-related visual loss are frequently heterogeneous, subtle or atypical, contributing to delayed recognition and poor outcomes. This case series describes the visual presentations, warning symptoms and visual outcomes of patients with confirmed GCA-related vision loss managed at a district general hospital. By integrating these observations with existing literature, this article explores recurring patterns, diagnostic pitfalls and clinical reflections relevant to trainees across multiple specialties. The findings reinforce the need for a high index of suspicion, even in the absence of classical prodromal symptoms, and highlight the narrow therapeutic window for preventing irreversible visual impairment.
Introduction
Giant cell arteritis is the most common systemic vasculitis affecting older adults and represents a true ophthalmic emergency. Visual loss associated with GCA is typically sudden, profound and often irreversible, most commonly due to arteritic anterior ischaemic optic neuropathy, central retinal artery occlusion or, less frequently, posterior ischaemic optic neuropathy (1). Despite advances in diagnostic pathways and increasing awareness across specialties, permanent visual impairment remains common, with reported rates of visual loss ranging from 15–30% in contemporary cohorts (2).
Guidelines consistently emphasise early recognition and immediate initiation of high-dose corticosteroids (3). However, in day-to-day clinical practice, patients often present with visual symptoms that do not align neatly with classical teaching. Transient blurring, partial visual field loss or painless visual disturbance may precede catastrophic vision loss, while some patients experience visual failure without any recognised warning signs. These subtleties are frequently under-emphasised in training resources yet represent the scenarios in which diagnostic delay is most likely.
This article presents a case series of patients with confirmed GCA-related visual involvement. Rather than reiterating guideline recommendations alone, it aims to contextualise real-world presentation patterns and offer reflective learning points relevant to trainees involved in frontline care.
Methods
Patients were identified retrospectively through electronic clinical systems by reviewing records of individuals diagnosed with giant cell arteritis over a three-year period. Inclusion criteria were a confirmed diagnosis of GCA and documented visual symptoms or vision loss attributable to the disease. All data were anonymised at the point of collection, with no patient-identifiable information, dates or location-specific details included.
Extracted data included the nature and onset of visual symptoms, laterality, presence or absence of warning signs prior to permanent vision loss, and degree of visual recovery following treatment. The approach was descriptive rather than comparative, focusing on clinically relevant patterns rather than intervention outcomes. Ethical approval was not required for this anonymised case series.
Spectrum of Visual Presentations
The twenty patients included demonstrated a wide spectrum of visual presentations. Sudden complete unilateral vision loss was common, but many patients initially described subtler symptoms such as intermittent blurring, partial visual field defects, transient obscurations or dark shadows. Some reported ocular discomfort or painful eye movements, while others experienced painless deterioration.
This variability mirrors previous findings that GCA-related visual symptoms may evolve over hours to days and are not always dramatic at onset (4). For trainees, this reinforces the importance of taking seemingly minor visual complaints seriously in older patients, particularly when systemic symptoms or inflammatory markers raise concern.
Unilateral involvement was more frequent than bilateral disease, consistent with published data (5). However, bilateral vision loss did occur and was associated with particularly poor outcomes.
Warning Signs: Present, Absent, or Missed?
Classical prodromal symptoms such as headache, jaw claudication and scalp tenderness were present in only around half of cases. A significant proportion of patients reported no clear warning signs prior to permanent visual loss, consistent with earlier studies showing that up to one third of patients with GCA-related visual loss lack classical systemic features (6).
Several patients experienced visual loss despite an established diagnosis of GCA and initiation of corticosteroid therapy, reinforcing that treatment does not eliminate risk entirely and that vigilance must continue after diagnosis (7).
A Clinical Vignette
An older patient presented to an emergency department with intermittent blurring in one eye over several days. They denied headache, jaw claudication or scalp tenderness and were systemically well. Initial examination revealed mildly reduced visual acuity but no obvious fundoscopic abnormalities. The symptoms were attributed to dry eye, and the patient was discharged with reassurance.
Two days later, they re-presented with sudden complete vision loss in the same eye. Subsequent investigations confirmed giant cell arteritis. Despite prompt high-dose corticosteroid treatment, vision did not recover.
This vignette reflects a recurring theme within this case series: early symptoms may be subtle, painless and easily misattributed, yet the consequences of delayed recognition are profound. For trainees, it highlights how reliance on classical features alone may provide false reassurance.
Visual Outcomes and Prognosis
Visual recovery was limited overall. Complete recovery was rare and generally confined to patients whose initial symptoms were partial or transient. Partial recovery occurred in a small number of cases, while most patients with complete vision loss experienced minimal or no improvement.
These outcomes align with existing literature, which consistently demonstrates that established GCA-related visual loss is often irreversible (8). The likelihood of recovery is closely related to the severity and duration of ischaemia, emphasising the narrow window for effective intervention (9).
Reflections for Trainees Across Clinical Practice
Several important reflections emerge from this case series that are relevant to all trainees involved in frontline care, including foundation doctors, general practice trainees and acute medical teams.
First, GCA-related visual loss is not always dramatic at presentation. Subtle or transient symptoms may precede irreversible damage. Trainees should resist the temptation to dismiss vague visual complaints in older patients, particularly when symptoms are new or evolving.
Second, absence of classical systemic features does not equate to low risk. While headache and jaw claudication are helpful diagnostic clues, their absence should not be used to downgrade concern when visual symptoms are present.
Third, visual loss may occur even after diagnosis and treatment initiation. This underscores the importance of close monitoring, clear safety-netting and rapid escalation of new symptoms.
Finally, these cases highlight the devastating functional and psychological impact of sudden vision loss. Trainees should remain mindful of the broader consequences for patients, including loss of independence and quality of life.
Conclusion
This case series illustrates the unpredictable and often subtle nature of visual loss in giant cell arteritis. Warning signs are not universal, early symptoms may be easily overlooked, and visual outcomes are frequently poor once permanent loss occurs. By integrating real-world clinical patterns with existing evidence, this article aims to support trainees across specialties in recognising GCA-related visual risk earlier and acting decisively. Improved awareness and timely intervention remain the most effective tools for preventing irreversible harm in this high-stakes condition.
References
- Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50–57. doi:10.1056/NEJMcp1214825.
- Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234–245.
- Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1–e23. doi:10.1093/rheumatology/kez672.
- Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125(4):509–520.
- Liu GT, Glaser JS, Schatz NJ, Smith JL. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology. 1994;101(11):1779–1785.
- Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84(5):269–276.
- Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology. 2003;110(6):1204–1215.
- Chen JJ, Leavitt JA, Fang C, Crowson CS, Matteson EL, Warrington KJ. Evaluating the incidence of arteritic ischemic optic neuropathy and other causes of vision loss from giant cell arteritis. Ophthalmology. 2016;123(9):1999–2003.
- Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis: report of a large study and review of the literature. Acta Ophthalmol Scand. 2002;80(4):355–367.